Cotización Nuvectis Pharma - NVCT

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

4.80

Postura de Compra

4.77

Postura de Venta

4.84

Volume Operado de la Acción

70,563

4.80 Rango del Día 5.15

4.685 Rango de 52 semanas 12.10

Capitalización de Mercado [m]

92.741M

Precio Anterior

5.07

Precio de Apertura

5.05

Hora

4.8

Última hora de negociación

10:00:36

Volumen financiero

US$ 346,937

Precio Promedio Ponderado

4.9167

Volumen promedio (3 m)

181,944

Acciones en circulación

19,320,973

Rendimiento del Dividendo

Ratio Precio/Utilidad

-4.14

Beneficio por acción (BPA)

-1.15

turnover

Beneficio neto

-22.26M

Nuvectis Pharma Inc is a biopharmaceutical company. Nuvectis Pharma Inc is a biopharmaceutical company.

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.nuvectis.com

Sede

Wilmington, Delaware, USA

Fundado

Nuvectis Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NVCT. The last closing price for Nuvectis Pharma was US$5.07. Over the last year, Nuvectis Pharma shares have traded in a share price range of US$ 4.685 to US$ 12.10.

Nuvectis Pharma currently has 19,320,973 shares in issue. The market capitalisation of Nuvectis Pharma is US$97.96 million. Nuvectis Pharma has a price to earnings ratio (PE ratio) of -4.14.

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma’s NXP900...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.29	-5.6974459725	5.09	6.55	4.685	597733	5.42722467	CS
4	-3.95	-45.1428571429	8.75	11.8	4.685	310838	7.31810794	CS
12	-2.67	-35.7429718876	7.47	11.8	4.685	181944	7.13151677	CS
26	-1.2	-20	6	11.8	4.685	127088	6.98477738	CS
52	-3.59	-42.789034565	8.39	12.1	4.685	108045	7.44547526	CS
156	0.85	21.5189873418	3.95	20.92	3.08	191936	7.89330364	CS
260	0.85	21.5189873418	3.95	20.92	3.08	191936	7.89330364	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 1.87 (90.82%)	102.31M
CRNCCerence Inc	US$ 5.25 (86.17%)	28.9M
BDRXBiodexa Pharmaceuticals PLC	US$ 6.42 (66.75%)	1.05M
SPAISafe Pro Group Inc	US$ 4.5315 (41.61%)	37.97M
NKGNNKGen Biotech Inc	US$ 0.42 (34.19%)	1.3M
PYXSPyxis Oncology Inc	US$ 2.06 (-46.07%)	8.89M
KURAKura Oncology Inc	US$ 9.90 (-37.77%)	7.26M
BLRXBioLineRx Ltd	US$ 0.357 (-34.52%)	5.51M
SHOTWSafety Shot Inc	US$ 0.1001 (-33.27%)	2.5k
APLMApollomics Inc	US$ 0.1109 (-25.97%)	4.76M
CDTConduit Pharmaceuticals Inc	US$ 0.1106 (19.83%)	475.34M
NVDANVIDIA Corporation	US$ 144.17 (-1.18%)	190.92M
AKTSAkoustis Technologies Inc	US$ 0.104 (19.40%)	179.81M
ELABElevai Labs Inc	US$ 0.0203 (-5.14%)	127.06M
WORXSCWorx Corporation	US$ 1.8799 (91.83%)	102.31M